Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass - Keymeulen, B; Walter, M; Mathieu, C (Diabetologia, 2010)
et al.